Key Highlights

  • Related party Revenue was USD 2.48 million, compared with USD 8.80 million.
  • Loss per share from continuing operations was USD 1.05.
  • Loss from operations was USD 32.21 million, compared with USD 8.98 million.
  • Cash and cash equivalents were USD 351.8 million at September 30, 2026.

Apnimed (NASDAQ:APMD) reported related party revenue of USD 2.48 million for the third quarter of 2026, compared with USD 8.80 million in the prior-year quarter. The loss from operations was USD 32.21 million, compared with USD 8.98 million, and basic and diluted loss per share from continuing operations was USD 1.05, compared with USD 1.83.

For the nine months ended September 30, 2026, related party revenue was USD 99.37 million, compared with USD 29.04 million, and income from operations was USD 24.14 million, compared with a loss of USD 42.03 million.

Operating Expenses

Research and development expenses were USD 11.81 million, compared with USD 9.75 million, and general and administrative expenses were USD 22.63 million, compared with USD 6.05 million. Cost of services to a related party was USD 245 thousand, compared with USD 1.99 million.

Total operating expenses were USD 34.69 million, compared with USD 17.79 million. The filing states that the company recognized incremental stock-based compensation expense of USD 3.1 million for the quarter as a result of award modifications.

Other Income and Nine-Month Results

Interest income was USD 1.81 million, compared with USD 263 thousand, and total other income was USD 2.68 million, compared with USD 263 thousand. The net loss from continuing operations before income taxes was USD 29.52 million, compared with USD 8.72 million.

For the nine months, the gain on Reversal of the deposit Liability was USD 57.12 million, and the Net Income from continuing operations before income taxes was USD 81.58 million, compared with a loss of USD 41.03 million. Basic Earnings Per Share from continuing operations for the nine months were USD 6.46 and Diluted Earnings per Share were USD 4.75, compared with a loss of USD 8.62.

Balance Sheet and Product Candidate

Cash and cash equivalents were USD 351.8 million at September 30, 2026, compared with USD 41.9 million at December 31, 2025. Total Assets were USD 371.5 million, compared with USD 72.9 million, and the accumulated Deficit was USD 233.2 million.

The filing states that the company's lead product candidate, AD109, with the proposed name Oxnimbi, is an investigational, fixed-dose oral combination of aroxybutynin and atomoxetine for the treatment of obstructive sleep apnea in adults and has completed Phase 3 clinical trials. The filing also states that all Accounts Receivable were related to Shionogi-Apnimed Sleep Science, LLC.

The filing states that in connection with the closing of its initial public offering, the company's outstanding convertible preferred stock, Class B common stock, Class C common stock and convertible notes automatically converted into 25,975,771 shares of Class A common stock. In April 2025, the company entered into an asset purchase agreement with Desitin and Cereus, pursuant to which it purchased sulthiame intellectual property and obtained a perpetual, irrevocable, exclusive and fully paid-up license to licensed sulthiame intellectual property.

The filing also describes a right of first negotiation agreement and a common stock purchase agreement with Shionogi entered into on November 1, 2023, and a Lease with a related party for office space entered into in June 2023.

Apnimed Q3 2026 Earnings: Key Takeaways

Apnimed reported third quarter 2026 related party revenue of USD 2.48 million and a loss per share from continuing operations of USD 1.05. Cash and cash equivalents were USD 351.8 million at September 30, 2026.